Centers for Disease Control and Prevention,National Center for HIV Viral Hepatitis STD and TB Prevention

This report discusses community health centers (CHCs) in routine HIV testing consistent with the 2006 recommendations issued by CDC. It explains why it is important for CHCs to routinely offer HIV testing and provides general protocol elements for facility-based HIV testing, such as ensuring confidentiality, implementing alternatives to opt-out HIV testing, testing alternatives and procedures, encouraging patients to return if a confirmatory HIV test is performed, and providing test results to patients.

This report summarizes laboratory and epidemiologic findings associated with reduced susceptibility to azithromycin. It notes that in August-October 2009, five of 55 N. gonorrhoeae isolates obtained from men with symptomatic urethritis tested at San Diego County’s main municipal STD clinic had high azithromycin minimum inhibitory concentrations (MIC)s.

This report describes tests of an analysis of data from five laboratories that used reverse sequence screening during 2006-2010 to identify persons with possible untreated syphilis. Three sites served patient populations with low prevalence of syphilis, and two sites served patient population with high prevalence. The results indicated that among sera reactive on initial screening with an automatable treponemal enzyme and chemiluminescence immunoassays (EIA/CIA), 56.7 percent had a nonreactive rapid plasma regain (RPR) test.

This poster explains that hepatitis can be transmitted through sex with an infected person and that men who have sex with men are at increased risk for hepatitis A and B. It promotes hepatitis prevention through vaccines.

This poster states that hepatitis B is a serious disease spread by sexual contact. It promotes vaccination as a way of preventing the disease.

This poster urges anyone who has ever injected drugs to get tested for hepatitis C.

This report discusses the sexually transmitted disease (STD), chlamydia, which is common among sexually active adolescents and young adults. It explains that although chlamydia may be asymptomatic, it can have serious consequences in females, including infertility; hence, the importance of chlamydia prevention. Screening females aged <25 years is ranked by the National Commission on Prevention Priorities as one of the 10 most beneficial and cost-effective prevention services, but it also is one of the most underutilized.

On October 25, 2011, the Advisory Committee on Immunization Practices (ACIP) recommended routine use of quadrivalent human papillomavirus (HPV) vaccine (HPV4; Gardasil, Merck & Co. Inc.) in males aged 11 or 12 years. ACIP also recommended vaccination with HPV4 for males aged 13 through 21 years who have not been vaccinated previously or who have not completed the 3-dose series; males aged 22 through 26 years may be vaccinated. These recommendations replace the October 2009 ACIP guidance that HPV4 may be given to males aged 9 through 26 years.

This report summarizes trends in cephalosporin susceptibility among N. gonorrhoeae isolates in the United States during 2000--2010 using data from the Gonococcal Isolate Surveillance Project (GISP). During that period, the percentage of isolates with elevated minimum inhibitory concentrations (MICs) to cephalosporins (=0.25 µg/mL for cefixime and =0.125 µg/mL for ceftriaxone) increased from 0.2% in 2000 to 1.4% in 2010 for cefixime and from 0.1% in 2000 to 0.3% in 2010 for ceftriaxone.

This visual file is a set of 30 slides providing information on the epidemiology of HIV infection through 2009.